Laura Benjamin

Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Ipsen Ltd. develops and markets medicinal products. The firm provides Decapepty, Disport, Hexvix, Increlex and Somatuline. The company is headquartered in Slough, the United Kingdom.

Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark.

Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ.

Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Ceterix Orthopaedics, Inc. develops novel surgical tools for arthroscopic procedures. It offers NovoStitch Pro Meniscal Repair System, a device designed to address complex meniscal tear patterns not adequately served by other repair systems. The company was founded by Justin Saliman and John G. McCutcheon in October 2010 and is headquartered in Fremont, CA.

Israel Advanced Technology Industries is an umbrella organization that represents the high-tech, life science, and other advanced technology industries. The private company is based in Hertzliya Pituach, Israel. The Israeli company was founded by Nechemia Jacob Peres, Aaron Mankovski, and Ruth Alon. The CEO is Karin Meir Rubinstein.

Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.

Chromaderm, Inc. operates as a clinical stage biotech company. It develops topical PKC-beta inhibitor. The company was founded by Barbara A. Gilchrest, Mark de Souza and James W. Fordyce and is headquartered in Cambridge, MA.

Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

Nan Fung Life Sciences (Nan Fung Life Sciences) is a venture capital subsidiary of Vervain Group (Holdings) Ltd founded in 1954 by Vincent Cheung. The firm is headquartered in Hong Kong.

Tactiva Therapeutics LLC operates as a development stage immuno-oncology company. The firm engages in developing the next generation of cancer immunotherapies by utilizing a new approach to cell therapy. The company was founded by Matthew E. Colpoys Jr., Richard C. Koya, and Kunle Odunsi and is headquartered in Buffalo, NY.

Engrail Therapeutics, Inc. acquires, develops and commercialize transformative medicines. The company was founded in 2019 and is headquartered in San Diego, CA.

Arctic Vision (Shanghai) Biotechnology Co., Ltd. is a Chinese Shanghai-based ophthalmic biotech company that focuses on developing innovative therapies to address unmet clinical needs and benefit ophthalmic patients. The company is led by an elite team of ophthalmic industry veterans with substantial experience in R&D and commercialization of eye care products. Arctic Vision has top-tier biotech venture capital investors with a broad network in both the U.S. and European ophthalmic markets, and an unprecedented track record in company incubation. The company was founded by Hai Di Hu, who has been the CEO since incorporation.

Chime Biologics Ltd. is a leading Contract Development and Manufacturing Organization (CDMO) that provides customer-centric and cost-effective outsourcing services for biopharmaceutical development and manufacturing. The company is based in Wuhan, China, and its world's first GE Kubio facility is located at Wuhan's Bio-Lake Biotech Industry Development Zone, with a clear path to expand the total capacity up to 140,000+ liters in the near future. The Chinese company has introduced the world's first modular biopharmaceutical plant, Kubio, which empowers its partners' success in biologics from cell line development to commercial manufacturing. Chime Biologics is committed to making cutting-edge biomedicines affordable and accessible to all patients, fulfilling its commitment to human health. Chime Biologics is ISO 14001:2015 and ISO 45001:2018 certified and has been providing customers with clinical materials for pre-clinical and clinical stages worldwide since 2016.